4.6 Article

Transglutaminase Is a Tumor Cell and Cancer Stem Cell Survival Factor

Journal

MOLECULAR CARCINOGENESIS
Volume 54, Issue 10, Pages 947-958

Publisher

WILEY
DOI: 10.1002/mc.22375

Keywords

cancer stem cells; epithelial-mesenchymal transition; EMT; transglutaminase; squamous cell carcinoma; epidermal cancer stem cells; ovarian cancer; pancreatic cancer; prostate cancer; glioma; breast cancer; drug resistance

Funding

  1. National Institutes of Health [R01 CA131064, R01 CA184027]
  2. American Cancer Society
  3. University of Maryland Greenebaum Cancer Center

Ask authors/readers for more resources

Recent studies indicate that cancer cells express elevated levels of type II transglutaminase (TG2), and that expression is further highly enriched in cancer stem cells derived from these cancers. Moreover, elevated TG2 expression is associated with enhanced cancer stem cell marker expression, survival signaling, proliferation, migration, invasion, integrin-mediated adhesion, epithelial-mesenchymal transition, and drug resistance. TG2 expression is also associated with formation of aggressive and metastatic tumors that are resistant to conventional therapeutic intervention. This review summarizes the role of TG2 as a cancer cell survival factor in a range of tumor types, and as a target for preventive and therapeutic intervention. The literature supports the idea that TG2, in the closed/GTP-binding/signaling conformation, drives cancer cell and cancer stem cell survival, and that TG2, in the open/crosslinking conformation, is associated with cell death. (C) 2015 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available